Guerbet
Corporate brand
UnclaimedGuerbet is a French medical-imaging company specializing in contrast agents and related imaging solutions.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Guerbet is a France-founded healthcare company focused on contrast agents used in medical imaging. Its products support diagnostic procedures in areas including magnetic resonance imaging and X-ray-based examinations. The company was established in 1926 by André Guerbet, whose family was closely associated with the early development of radiological contrast media: his father, Marcel Guerbet, is credited with discovering Lipiodol in 1901, an iodinated product used in the history of X-ray imaging. The business developed around the specialized requirements of radiology and has remained concentrated on medical imaging rather than operating as a diversified pharmaceutical conglomerate. Its scope includes contrast agents and associated application systems intended for use with imaging procedures. This positioning places Guerbet within a technically specialized segment of healthcare, where product performance, regulatory authorization, manufacturing quality, supply reliability, and compatibility with clinical workflows are important competitive factors. Guerbet has an international operating footprint. The reference material identifies manufacturing facilities in France, Ireland, Canada, North Macedonia, the United States, and Brazil, while the company serves markets beyond its home country. Its headquarters were formerly in Villepinte, France, and the supplied reference identifies Chicago as its current headquarters. The international manufacturing network supports the company's presence in major diagnostic-imaging markets and reflects the regulatory and supply-chain requirements of contrast-media production. A significant expansion took place in 2015, when Guerbet announced the acquisition of part of Mallinckrodt's contrast-media and application-systems divisions. The transaction was announced in July and completed in November of that year. The deal strengthened Guerbet's portfolio and expanded its commercial and operational reach in the contrast-media sector. The company also continued to develop products for magnetic resonance imaging. In 2022, the United States Food and Drug Administration approved Elucirem, the brand name for gadopiclenol, as an MRI contrast agent. The reference material states that Elucirem would be manufactured at Guerbet's facility in Raleigh, North Carolina, and at three French factories. The approval represented an important regulatory and product-development milestone for the group in the United States. Guerbet is listed on Euronext Paris under the ticker GBT. A reference describing the company's 2017 performance reported revenue of €807.1 million and a workforce of more than 2,700 people worldwide; those figures are historical and should not be treated as current company metrics. Industry analysis cited in the supplied material identified Guerbet as a key participant in the global contrast-media market, which was valued at approximately $6.19 billion in 2023. Overall, Guerbet's identity is built around specialized medical-imaging expertise, a heritage in contrast media, international manufacturing, and the development and commercialization of products used in radiological diagnosis.
History
Guerbet's history is rooted in the early development of radiological contrast media. In 1901, Marcel Guerbet discovered Lipiodol, an iodinated product associated with the first generation of contrast agents used in X-ray imaging. This scientific and commercial heritage later became the foundation for the company established by his son, André Guerbet, in 1926. From its foundation, Guerbet developed as a specialist healthcare business rather than a broad-based pharmaceutical group. Its principal field has been contrast media for diagnostic imaging, a category in which products must satisfy demanding clinical, manufacturing, and regulatory requirements. The company's activities have included agents used in MRI and X-ray-based imaging, as well as systems used to administer contrast media during examinations. Over time, Guerbet expanded beyond France and built an international manufacturing and commercial presence. The supplied reference identifies production facilities in France, Ireland, Canada, North Macedonia, the United States, and Brazil. This footprint reflects the company's effort to serve multiple regulated markets and to maintain geographically distributed manufacturing capacity. The company was historically headquartered in Villepinte, France, while the supplied reference identifies Chicago as its current headquarters. A major corporate development occurred in 2015. In July of that year, Guerbet announced the planned takeover of part of Mallinckrodt's contrast-media and application-systems divisions. The transaction was completed in November 2015. By adding assets and activities from an established industry participant, Guerbet increased the scale of its core contrast-media business and broadened its portfolio of imaging-related operations. Guerbet's more recent development has included investment in MRI contrast products. In 2022, the FDA approved Elucirem, or gadopiclenol, as an MRI contrast agent. The product was scheduled to be produced at Guerbet's Raleigh, North Carolina facility and at three factories in France. The approval gave the company an important presence in the United States MRI contrast market and demonstrated the continuing role of regulatory approvals in the group's product strategy. The company is publicly traded on Euronext Paris under the ticker GBT. Historical reference material reported 2017 revenue of €807.1 million and more than 2,700 employees worldwide. These figures describe that period only. Guerbet continues to be characterized by its concentration on medical imaging, its international production network, and its long-standing association with contrast-agent innovation. Its competitive position is based on specialized know-how, product approvals, manufacturing capability, and relationships with healthcare providers and imaging professionals rather than on consumer-facing brand awareness.
- 2022
Elucirem approved in the United States
[1]The FDA approved Elucirem, or gadopiclenol, as an MRI contrast agent.
- 2015
Mallinckrodt transaction completed
[1]Guerbet completed its acquisition of part of Mallinckrodt's contrast-media and application-systems divisions after announcing the deal in July.
- 1926
Company founded
[1]André Guerbet founded the company that bears the Guerbet name, building on the family's history in radiological contrast media.
- 1901
Discovery of Lipiodol
[1]Marcel Guerbet discovered Lipiodol, an iodinated product identified with the early history of X-ray contrast agents.
Products and positioning
A specialized international healthcare company focused on contrast agents and associated systems for diagnostic medical imaging, combining a long French radiology heritage with regulated global manufacturing and commercialization.
MRI contrast agent · 2022
Elucirem
Elucirem is Guerbet's brand for gadopiclenol, a magnetic-resonance-imaging contrast agent. The United States FDA approved it in 2022. The supplied reference states that Guerbet planned to manufacture the product at its Raleigh, North Carolina facility and at three French factories, linking the product to the company's international production network.
Iodinated contrast medium
Lipiodol
Lipiodol is an iodinated product discovered by Marcel Guerbet in 1901 and associated with the early development of X-ray contrast media. It represents the historical scientific foundation of the Guerbet name and the company's long-standing connection with radiological imaging.
Brand decisions
2022
United States launch pathway for EluciremProduct launchBackground
Guerbet pursued regulatory approval for gadopiclenol as a new MRI contrast agent in the United States.
Action taken
The FDA approved the product under the brand name Elucirem and Guerbet identified manufacturing sites in North Carolina and France.
Aftermath
The approval expanded Guerbet's approved MRI contrast-agent portfolio in the United States.
2015
Acquisition of selected Mallinckrodt imaging assetsM&ABackground
Guerbet sought to expand its specialist contrast-media and imaging-systems business through a transaction involving selected Mallinckrodt divisions.
Action taken
The company announced the transaction in July 2015 and completed it in November of the same year.
Aftermath
The deal broadened Guerbet's activities and international scale in its core contrast-media market.
Recent events
Reported
Guerbet launches OptiProtect 3S[3]
Guerbet announced the launch of OptiProtect 3S, a suite of technical services and support for its injection solutions.
Reported
Guerbet and InterSystems announce strategic partnership[4]
Guerbet announced a strategic partnership with InterSystems to optimize integration of the Contrast&Care injection management solution into hospital and medical imaging center IT systems.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/guerbet · Editorial policy · How profiles are compiled